~~<i id='47D43EABD6'><strike id='47D43EABD6'><tt id='47D43EABD6'><pre id='47D43EABD6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：focus 2025-09-27 13:09:39 - browse：46

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Bright Health sells Medicare Advantage business to Molina

hotspot

explore

leisure time

MattRourke/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsle

WSS

New air purifier tech could be key to improving indoor air quality

PBM executives asked to testify by House panel

Empower primary care with adequate payments and technology

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Chemotherapy before breast cancer surgery might fuel metastasis

Primary care doctor shortage won't be solved by free med school tuition

explore

explore

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Is it ever OK for doctors to lie to their patients?

Apple is now the first public company to be valued at $3 trillion

AI for drug discovery: Experts on separating hype from reality

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Alkermes shareholders re

Duchenne breakthrough therapy leaves behind pioneering families

Welsh Carson private equity firm escapes from FTC antitrust case

Dobbs anniversary: the lost opportunity of abortion as health care

Moonlake's readout produced a cash windfall. Risks remain

hotspot

As billionaires fund anti

Jerome Adams on the need for new antivirals for Covid

Empower primary care with adequate payments and technology

Supreme Court strikes down use of affirmative action

Tori Bowie and the unacceptable rates of Black maternal death

Medical records are filled with copy

explore

explore

explore

leisure time